GRI Bio Q3 2026 Results: Net Loss of $1.51M, Loss Narrows
GRI Bio, Inc. reported a net loss of $5.15 million for the nine months ended September 30, 2026, a significant reduction from the $9.30 million loss in the prior year period, primarily due to lower research and development expenses. The company strengthened its liquidity through an ATM offering, ending the period with $9.47 million in cash and cash equivalents. GRI Bio remains a clinical-stage biopharmaceutical company with an accumulated deficit of $56.84 million and no significant revenue.
- Key figure
- Net loss $1.51M